Please login to the form below

Not currently logged in
Email:
Password:

Isis Pharmaceuticals

This page shows the latest Isis Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Merck & Co wins hepatitis C patent dispute with Gilead

Merck & Co wins hepatitis C patent dispute with Gilead

Pharmaceuticals (formerly known as Isis Pharma).

Latest news

  • Roche buys rare disease firm Trophos in €470m deal Roche buys rare disease firm Trophos in €470m deal

    SMA therapy in development at Cytokinetics, while Biogen Idec and Isis Pharmaceuticals are also developing ISIS-SMNRx for the disease, a drug due to enter phase III soon.

  • Janssen partners with Isis on stomach conditions Janssen partners with Isis on stomach conditions

    Janssen Biotech will make use of Isis Pharmaceuticals' RNA technology to develop new treatments for genetic diseases of the stomach. ... B Lynne Parshall, chief operating officer at Isis Pharmaceuticals, said: "We are the leader in RNA-targeted

  • Pharma companies back Rare Disease Day Pharma companies back Rare Disease Day

    Other life sciences companies to support Rare Disease Day include Isis Pharmaceuticals, NPS Pharmaceuticals, Quintiles and Shire.

  • Isis rises on positive triglyceride drug data Isis rises on positive triglyceride drug data

    Antisense specialist Isis Pharmaceuticals shares leapt this week after the company reported positive data with its triglyceride-lowering drug candidate. ... said Isis' head of development Richard Geary on a conference call to discuss the results.

  • Isis drops arthritis candidate Isis drops arthritis candidate

    Isis drops arthritis candidate. ISIS-CRP Rx disappoints in phase II. Isis Pharmaceuticals is to cut back on its ambitions for antisense candidate ISIS-CRP Rx after it dropped investigations for ... Isis is evaluating the effect of lowering CRP on the

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    Bayer is not the only company targeting OTC; Perrigo announced the acquisition of the Belgian OTC company Omega Pharmaceuticals with its 2, 000 product portfolio for $4.5bn. ... AZ also announced a strategic alliance with ISIS Pharmaceuticals building on

  • Pharma deals during June 2014 Pharma deals during June 2014

    its partner Isis Pharmaceuticals a $15m milestone. ... Hot gossip. Rumours were posted by the Financial Times that Shire was about to make a $5bn bid for NPS Pharmaceuticals.

  • Pharma deals during September 2013 Pharma deals during September 2013

    Cementing relationships. Merck Serono and Ablynx are not the only companies deepening their relationship with a fourth deal; Biogen Idec and Isis Pharmaceuticals have a similarly intense relationship with four deals ... Their latest deal is a six year

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    480. Isis Pharmaceuticals/ Roche. Collaboration. To develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology. ... TaslyDiyi Pharma/ Tasly Pharmaceuticals. Acquisition. Maker of chemical drugs. 240. Bavarian Nordic/

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Shires's Jeffrey Jonas to lead Sage Shires's Jeffrey Jonas to lead Sage

    His roles prior to joining Shire include serving as executive VP of Isis Pharmaceuticals and chief medical officer of Forest Laboratories. ... Her previous positions include VP, finance, for Cyberkinetics Neurotechnology Systems, as well as senior

  • Shire promotes Dr Jeff Jonas to lead regenerative medicines business Shire promotes Dr Jeff Jonas to lead regenerative medicines business

    Dr Jonas moved to Shire in 2008, prior to which he served as executive vice president at Isis Pharmaceuticals in charge of clinical and pre-clinical development, regulatory affairs, quality assurance ... senior member of the Shire specialty

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics